| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYB5A |
| Uniprot No | P00167 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-108aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMAEQSD EAVKYYTLEE IQKHNHSKST WLILHHKVYD LTKFLEEHPG GEEVLREQAG GDATENFEDV GHSTDAREMS KTFIIGELHP DDRPKLNKPP ETLITTIDSS SS |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **CYB5A 重组蛋白**的参考文献示例(内容为虚构，仅作格式参考)：
---
1. **文献名称**: *"Expression and Functional Characterization of Recombinant Human CYB5A in Escherichia coli"*
**作者**: Zhang, L.; Wang, Y.; Chen, H.
**摘要**: 本研究通过大肠杆菌系统成功表达并纯化重组人源CYB5A蛋白，验证其与细胞色素P450酶系的相互作用，证实其在药物代谢中的电子传递功能。
2. **文献名称**: *"Structural Insights into CYB5A Reductase Activity via Recombinant Protein Crystallography"*
**作者**: Smith, J.R.; Tanaka, K.; Müller, P.
**摘要**: 利用重组CYB5A蛋白的晶体结构分析，揭示了其血红素结合域的关键氨基酸残基，阐明了其在氧化还原反应中的催化机制。
3. **文献名称**: *"Role of Recombinant CYB5A in Modulating Lipid Peroxidation in Hepatocytes"*
**作者**: Gupta, S.; Lee, T.; Park, S.
**摘要**: 通过体外实验证明，重组CYB5A蛋白通过调节脂质过氧化过程保护肝细胞免受氧化损伤，为代谢性疾病研究提供新方向。
4. **文献名称**: *"High-Yield Production of Functional CYB5A Recombinant Protein for Biomedical Applications"*
**作者**: Rossi, M.; González, A.; Silva, R.
**摘要**: 开发了一种高效的真核表达系统(CHO细胞)生产功能性CYB5A重组蛋白，优化后的蛋白适用于血细胞疾病模型的治疗研究。
---
如需真实文献，建议通过PubMed、Google Scholar等平台以关键词“CYB5A recombinant protein”或“cytochrome b5 reductase expression”检索。
CYB5A (cytochrome b5 type A) is a small heme-binding protein that plays a critical role in electron transfer reactions across cellular membranes. Encoded by the CYB5A gene in humans, it is ubiquitously expressed, particularly in the liver, erythrocytes, and adrenal glands. Structurally, CYB5A consists of a hydrophilic catalytic domain anchored to membranes via a hydrophobic C-terminal tail. It localizes primarily to the endoplasmic reticulum (ER) and mitochondrial outer membrane, where it interacts with redox partners such as cytochrome P450 enzymes and fatty acid desaturases.
Functionally, CYB5A acts as an electron donor in diverse metabolic processes. It supports cytochrome P450-mediated oxidation of drugs, steroids, and xenobiotics, enhancing detoxification and biosynthesis pathways. Additionally, it participates in fatty acid desaturation by transferring electrons to Δ5 and Δ6 desaturases, influencing lipid metabolism. CYB5A also contributes to methaemoglobin reduction in erythrocytes, maintaining haemoglobin’s oxygen-carrying capacity. Dysregulation of CYB5A has been linked to metabolic disorders, anaemia, and altered drug metabolism.
Recombinant CYB5A protein is produced using heterologous expression systems (e.g., E. coli, yeast, or mammalian cells) to study its biochemical properties and interactions. Purification typically involves affinity chromatography leveraging tags like His-tag or GST. This recombinant tool enables in vitro studies on electron transport mechanisms, enzyme kinetics, and structure-function relationships. Its applications extend to drug discovery, where it aids in assessing cytochrome P450 activity and drug-drug interactions. Furthermore, recombinant CYB5A is used to investigate genetic variants associated with diseases, such as CYB5A mutations causing recessive congenital methaemoglobinaemia. By providing a controlled source of functional protein, recombinant CYB5A remains vital for advancing research in redox biology, pharmacology, and metabolic disease.
×
